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Samples were extracted with dichloromethane and the organic layer evaporated to dryness. The residue 
was dissolved in methanol, and 25 µl aliquot injected onto the column. Tolbutamide was used as the 
internal standard for chlorpropamide. The UV detector response was linear over the range 0 – 300 
µg/ml, with a correlation coefficient of 0.999 and detection limit of 1.30 ng/ml. Within day and between-
day assay variations was generally < 2.50%. No interference from endogenous constituent was 
observed. The utility of the method was demonstrated by determine chlorpropamide in samples from 
human volunteers following a single oral dose of 250 mg in drug interaction studies. The procedure is 
simple and fast, requiring small volumes of plasma. 
 





A single extraction step column chromatographic assay 
method which is highly sensitive is described for routine 
monitoring aimed at correlating chlorpropamide plasma 
levels with clinical effect. Chlorpropamide belongs to the 
sulphonlurea group of hypoglycemic agents. Chlorpropa-
mide has been in use for a number of years and it is 
known that wide intra-individual variation is often present 
after similar therapeutic doses (Hill and Crechoolo, 1978) 
and its therapeutic index is fairly low. Several analytical 
techniques have been employed in the analysis of sulph-
onylurea compounds from biological samples, the most 
frequently used being gas chromatography (Hartivig et 
al., 1980). The sensitivity of this method and the shorten 
time of analysis are advantages over older HPLC 
methods (Bakare et al., 1994; Chua et al., 1998). The 
single extraction procedure is also an advantage over a 
recent method (Kumasaka et al., 2005). The method 
developed can be used to monitor the plasma concen-
trations of the drugs in human subjects and elucidate 
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EXPERIMENTAL 
 
Optimised HPLC conditions 
 
The chromatograms were from an Agilent 1100 series quartenary 
LC pump system, equipped with ultraviolet detector, wavelength for 
detection was 276 nm. The stationary phase was a silica-based 
ultrasphere C18 column (5 mm, 2.0 mm × 25 cm). 
The mobile phase was methanol: 0.2% acetic acid in the ratio of 
3: 2; adjusted to pH 3.0 with perchloric acid. The operating tempe-
rature was ambient and the flow rate was 0.35 ml / min., with an 
operating pressure of 2000 psi. The sensitivity was maintained at 
0.10 a.u.f.s. A short acetonitrile wash (20 min, at 1 ml/min) at the 
end of each day was included to remove strongly retained solutes 





All chemicals and reagents were analytical or HPLC grade. Chlor-
propamide tablets were manufactured and the reference standard 
was donated by Neimeth International Pharm. Limited, Nigeria. 
Tolbutamide reference standard was donated by Alpharma (Form-
erly Cox Pharmaceuticals) Limited, UK. HPLC grade solvents and 
water were obtained by filtration through 0.45 um filters (Millipore 
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Figure 1. Effect of methanol on peak resolution during rapid 
high performance liquid chromatographic determination of chlor-
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Figure 2. Effect of 0.2% acetic acid on peak resolution during 
rapid high performance liquid chromatographic determination 




and tolbutamide) were prepared by dissolving 50 mg of the 
reference sample in 1 ml of 0.1 M sodium hydroxide and diluting to 
50 ml with filtered water. These solutions were found stable up to 5 
months at 4°C storage condition. Working solutions of appropriate 
concentrations were prepared every week by dilution of the stock 
solution with filtered water. The calibration curve standards were 
prepared by spiking drug-free human plasma with known amounts 
of chlorpropamide (1 – 50 ug/ml) and tolbutamide (50 ug) as 
internal standard.  
 
 
Extraction procedure  
 
Equal volumes (0.5 ml) of plasma, tolbutamide, and 0.1 M HCI were 
mixed together with 3 ml of dichloromethane and the mixture were 
vortexed for 15 s centrifuged at 2000 rpm for 3 min and the aqueo-
us layer aspirated. An aliquot of dichloromethane was removed and 
evaporated to dryness on a water bath at 40°C.  The  dried  residue  




was dissolved with 50 l of methanol, and 25 l of the solution were 
injected on to the column.  
 
 
Calibration curve and assay 
 
The calibration curve which was based on peak-area ratios to the 
concentrations of the drug, were prepared by spiking drug free 
serum with a standard chlopropamide (1 g/ml) to give a concen-
tration range of 1 – 50 g/ml and 50 g of the tolbutamide was 
added. The level of chlopropamide was derived from these values.  
 
 
Precision and sensitivity  
 
Assay precision was determined by the analysis of drug-free human 
plasma spiked with known concentrations of chlopropamide. The 
coefficient of variation (CV) at four different concentrations of plas-








Drug-free human plasma was spiked with known amount 
of chlorpropamide and tolbuamide (i.e), and extraction 
carried out with the most suitable solvent (dichlorome-
thane) under different pH conditions 3 - 7 to compare 
extractability and plasma backgrounds. The average yield 
at pH 3 was 98.87, 87.66% at pH 4; 82.74% at pH 5. Low 
yield of 45.30% was obtained at pH 6 and 7.  
Coefficient of variation of assay within day gave 2.1% 
at 1 g/ml, 1.9% at 5 g/ml, 0.96% at 30 g/ml and 0.43 
at 40 g/ml. Between day assay gave 2.7 at 1 g/ml, 2.2 
at 5 g/ml, 1.80 at 30 g/ml and 1.2% at 40 g/ml. The 
coefficient of variation for within day and between day 
assays at 1.30 g/ml was 0.2 and 1.9%, respectively.   
 
 
Optimisation of method 
 
The influence of mobile phase composition on the 
resolution (R) of peaks was assessed. Resolution (R) 
decreases when the methanol (Figure 1) component was 
increased (10 - 90%); and increases following increase in 
the 0.2% acetic acid (Figure 2). At different pH of the 
mobile phase (Figure 3), the peak area of the two drugs 
increases as the methanol component increases. There 
was a poor separation of peaks at a pH range of 3 – 5 
with a corresponding decrease in resolution (R). There 
was an increase in resolution when the flow rate was 
decreased (1 – 0.35 ml/min.), and again fell bellow 0.35 
ml/min (Figure 4). The best resolution of peaks and the 
highest detector response was obtained when the mobile 
phase composition (methanol: 0.2% acetic acid) was 
maintained at 60%: 40% respectively; and with the pH of 
the mixture adjusted to 3; and the flow rate kept at 0.35 
ml/min. A typical chromatogram for extracted plasma is 
shown (Figure 5). No interference  from  normal  endoge- 



























Figure 3. Effect of pH on peak resolution during rapid high 
performance liquid chromatographic determination of chlorpropa-


























Figure 4. Effect of flow rate on peak resolution during rapid high 
performance liquid chromatographic determination of 




nous plasma constituents was observed. The retention 
times of chlorpropamide and tolbutamide (i.s) were 9 and 
10.3 min, respectively.   
 
 
Application of the method  
 
The utility of the procedure described was demonstrated 
in the analysis of chlorpropamde in plasma samples for 3 
groups (I, II and III) of human (n = 6) volunteers following 
pharmacokinetic drug interaction study. The mean plas-
ma profiles of the 3 control groups following oral adminis-
tration of 250 mg chlorpropamide tablet alone are shown 
in Figure 6. The mean plasma concentration values of 







Figure 5.  High performance liquid chromatograms of an 
extract of blank plasma containing chlorpropamide and 




































Figure 6. Mean plasma profiles of 3 (I, II, III) control groups 




oral administration of 250 mg chlorpromide alone are in 
agreement with the value obtained by previous workers 
(Balant, 1981; Bakare et al., 1994).  
This report validates the utility and suitability of this 





mide monitoring in clinical therapy. Concentration as low 
as 1.30 ng/ml can be detected by this procedure as 
against 3.5 ng/ml using GS-MS method (Chua et al., 
1998).  
The assay requires simple materials and it is suffi-
ciently selective and sensitive to allow accurate and rapid 
therapeutic monitoring of plasma concentration of chlor-





The reference samples supplied by Neimeth International 
Pharmaceutical Limited, Nigeria, Alpharma Pharmaceu-
tical Limited, U.K (formerly Cox Pharmaceuticals), and 
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